Waldenstrom's Macroglobulinemia Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Enhancing Plasmapheresis Efficacy in Waldenstrom Macroglobulinemia: Overcoming Circuit Clotting Challenges
Semin Dial. 2024 Mar 20. doi: 10.1111/sdi.13206. Online ahead of print.NO ABSTRACTPMID:38506146 | DOI:10.1111/sdi.13206 (Source: Seminars in Dialysis)
Source: Seminars in Dialysis - March 20, 2024 Category: Urology & Nephrology Authors: Urvashi Khan Sourabh Sharma Pallavi Prasad Anupam Agarwal Ankur Jain Aditi Jain Himanshu Verma Source Type: research

Design and Rationale of Prolonged Nightly Fasting for Multiple Myeloma Prevention (PROFAST): Protocol for a Randomized Controlled Pilot Trial
CONCLUSIONS: PROFAST serves as an important first step in exploring the premise that prolonged nightly fasting is a strategy to control obesity and obesity-related mechanisms of myelomagenesis. In evaluating the feasibility and impact of prolonged nightly fasting on body composition, bone marrow adipose tissue, and biomarkers of tumor burden, this pilot study may generate hypotheses regarding metabolic mechanisms underlying MM development and ultimately inform clinical and public health strategies for MM prevention.TRIAL REGISTRATION: ClinicalTrials.gov NCT05565638; http://clinicaltrials.gov/ct2/show/NCT05565638.INTERNATIO...
Source: Cancer Control - March 11, 2024 Category: Cancer & Oncology Authors: David J Lee Elizabeth K O'Donnell Noopur Raje Cristina Panaroni Robert Redd Jennifer Ligibel Dorothy D Sears Omar Nadeem Irene M Ghobrial Catherine R Marinac Source Type: research

There’s life in the old dog yet: immunochemotherapy in Waldenström’s macroglobulinemia
Leukemia, Published online: 07 March 2024; doi:10.1038/s41375-024-02195-wThere’s life in the old dog yet: immunochemotherapy in Waldenström’s macroglobulinemia (Source: Leukemia)
Source: Leukemia - March 7, 2024 Category: Hematology Authors: Efstathios Kastritis Christian Buske Source Type: research

Invasive Aspergillosis with Impaired Neutrophil Responses against Aspergillus fumigatus in Patients Treated with Acalabrutinib – findings from three cases
B-cell malignancies such as chronic lymphocytic leukemia (CLL) or Waldenstrom's macroglobulinemia are now commonly treated with inhibitors of Bruton's tyrosine kinase (BTK). Ibrutinib is a first-generation covalent BTK inhibitor (BTKi) and that was the first of its kind to be approved by the FDA. Ibrutinib was found to be a risk factor for the occurrence of invasive fungal complications, mainly invasive aspergillosis, of which up to 40% were complicated by cerebral involvement[1]. (Source: International Journal of Infectious Diseases)
Source: International Journal of Infectious Diseases - March 7, 2024 Category: Infectious Diseases Authors: Marion Blaize, Guillaume Thizy, Alexandre Boissonnas, Ana ïs Portalier, Fanny Lanternier, Clémentine de La Porte des Vaux, Felipe Suarez, Marie-Elisabeth Bougnoux, Juliette Guitard, Arnaud Jabet, Nicolas Stocker, Abdelmalek Aoudjhane, Damien Roos-Weil, Tags: Case Report Source Type: research

Serum CXCL13 level is related to treatment response and predicts disease prognosis in Waldenstr öm macroglobulinemia
AbstractWaldenstr öm macroglobulinemia (WM) is a type of B-cell lymphoma that produces IgM. Our study aimed to investigate the role of CXCL13, a chemokine essential for B lymphocytes, in the evaluation of treatment response and prognosis in WM. We collected serum samples and clinical data from 72 WM patients, with 6 9 patients receiving systemic therapy and 3 patients opting not to receive treatment. Serum CXCL13 levels at baseline and after six months of treatments were measured by enzyme-linked immunosorbent assay. The median serum level of CXCL13 was 1 539.2 pg/ml (range 10.0–21 389.9) at baseline and sig nificantly...
Source: Annals of Hematology - March 6, 2024 Category: Hematology Source Type: research

How to manage waldenstr öm’s macroglobulinemia in 2024
Waldenstr öm’s Macroglobulinemia (WM) belongs to the group of indolent B-cell lymphomas. It is seen as a clinicopathological entity characterized by the infiltration of the bone marrow by lymphoplasmacytic lymphoma, and the presence of monoclonal IgM paraprotein in the serum [1,2]. By this, this lymphoma c auses symptoms due to lymphoma infiltration, such as anemia or lymph node enlargement, well known from other nodal B-cell lymphomas e.g. follicular lymphoma, as well as symptoms due to the IgM protein causing symptoms such as neuropathy, hemolysis or hyperviscosity [3]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 5, 2024 Category: Cancer & Oncology Authors: Alexander Grunenberg, Christian Buske Tags: Tumour Review Source Type: research

Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88L265P and CXCR4 mutations and underlying haemopathy
ConclusionsMYD88L265P mutation and underlying haemopathies are not predictive of a more severe disease. However, in cases of resistant and progressive neuropathy, they provide an opportunity to prescribe newly available drugs such as Bruton tyrosine kinase inhibitors. (Source: Journal of Neurology)
Source: Journal of Neurology - February 26, 2024 Category: Neurology Source Type: research

Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemia
Leukemia, Published online: 26 February 2024; doi:10.1038/s41375-024-02162-5Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemia (Source: Leukemia)
Source: Leukemia - February 26, 2024 Category: Hematology Authors: Ruth de Tute Nicholas Counsell Laura Clifton-Hadley Shirley D ’Sa Guy Pratt Gavin Campbell Lauren Campbell Ross Sadler William Townsend Bilyana Popova Paul Smith Oliver Schofield Roger Owen Rebecca Auer Source Type: research

Dutcher bodies in a Waldenstr öm Macroglobulinaemia patient
Ann Biol Clin (Paris). 2023 Dec 1;81(6):651-652. doi: 10.1684/abc.2023.1855.NO ABSTRACTPMID:38391170 | DOI:10.1684/abc.2023.1855 (Source: Annales de Biologie Clinique)
Source: Annales de Biologie Clinique - February 23, 2024 Category: Biochemistry Authors: Anne Checkouri Carole Humbert Yazid Arkam Agathe Debliquis Source Type: research

Dutcher bodies in a Waldenstr öm Macroglobulinaemia patient
Ann Biol Clin (Paris). 2024 Feb 24;81(6):651-652. doi: 10.1684/abc.2023.1855.NO ABSTRACTPMID:38391170 | DOI:10.1684/abc.2023.1855 (Source: Annales de Biologie Clinique)
Source: Annales de Biologie Clinique - February 23, 2024 Category: Biochemistry Authors: Anne Checkouri Carole Humbert Yazid Arkam Agathe Debliquis Source Type: research